Kyntra Bio (KYNB) Stock Statistics & Valuation Metrics

Kyntra Bio has a market cap or net worth of CHF21.62M. The enterprise value is -CHF9.07M.

Kyntra Bio has ― shares outstanding. The number of shares has decreased by -2.65% in one year.

Kyntra Bio’s return on equity (ROE) is -6.11 and return on invested capital (ROIC) is -50.72%.

The current PE Ratio of Kyntra Bio is 0.2. Kyntra Bio’s PEG ratio is -0.00002.

In the last 12 months, Kyntra Bio had revenue of 6.44M and earned 183.45M in profits. Earnings per share was 45.37.

In the last 12 months, operating cash flow was -21.38M and capital expenditures -22.00K, giving a free cash flow of -21.40M billion.

Kyntra Bio pays an annual dividend of ―, resulting in a dividend yield of ―

Kyntra Bio upcoming earnings date is Aug 10, 2026, After Close (Confirmed).

Kyntra Bio as a current ratio of 3.39, with Debt / Equity ratio of -43.94%

In the past 12 months, Kyntra Bio has paid -90.00K in taxes.

Kyntra Bio EV to EBITDA ratio is -1.26, with an EV/FCF ratio of -15.20.

Kyntra Bio has CHF87.24M in cash and marketable securities with CHF19.25M in debt, giving a net cash position of CHF67.99M billion.

Gross margin is 45.11%, with operating margin of -712.66%, and net profit margin of 2848.63%.

The average price target for Kyntra Bio is CHF29.10, which is 11.43% higher than the current price. The consensus rating is Moderate Buy